Stem Cell Therapy Market 2019 Analysis by Key Players, Share, Trend, Segmentation and Forecast to 2026 – Instant Tech News

Verified Market Research recently added a research report titled, Stem Cell Therapy Market Size and Forecast to 2026. The research report represents the potential growth opportunities that prevail within the global market. The report is analyzed on the idea of secondary research methodologies acquired from historic and forecast data. The Stem Cell Therapy market is expected to grow substantially and thrive in terms of volume and value during the forecast period. The report will provide an insight into the growth opportunities and restraints that construct the market. Readers can gain meaningful comprehension about the future of the market.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

Request a Sample of this report @ https://www.verifiedmarketresearch.com/download-sample/?rid=24113&utm_source=OMR&utm_medium=001

Top 10 Companies in the Stem Cell Therapy Market Research Report:

Osiris Therapeutics, Medipost Co., Anterogen Co., Pharmicell Co., HolostemTerapieAvanzateSrl, JCR Pharmaceuticals Co., Nuvasive, RTI Surgical, Allosource

Competitive Landscape

The insightful research report on the Stem Cell Therapy market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior. It helps the reader understand the strategies and collaborations that players are that specialize in combat competition within the market. The comprehensive report provides a big microscopic check out the market. The reader can identify the footprints of the manufacturers by knowing about the worldwide revenue of manufacturers, the worldwide price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

Global Stem Cell Therapy Market: Drivers and Restraints

The report offers underlying drivers that compel the consumers to take a position within the products and services. The detailed information assists readers in understanding the requirements of consumer demands. The report provides drivers at the local and global levels to assist determine the economic process . This information will help readers decide potential strategies that can help them stay ahead in the competitive industry.

Restraints provided in this section of the report contrasts the drivers segment as it explains the factors that can hamper the growth of the Stem Cell Therapy market during the forecast period. Restraints play a pivotal role in the global and regional market as it bends the prospective opportunities in the market. Readers can weigh and asses the drivers and restraints before making any investments or strategies.

Global Stem Cell Therapy Market: Segment Analysis

The report includes major segments like product type and end-user that provide an array of components that determine the portfolio of the Stem Cell Therapy industry. Each type furnishes information regarding the sales value during the forecast period. The understanding of the segment directs the readers in recognizing the importance of things that shape the market growth.

Global Stem Cell Therapy Market: Regional Analysis

This section of the report provides detailed information about each region and how numerous factors of that particular region affect the growth of the Stem Cell Therapy market. The government policies, weather, politics, and other factors determine the longer term of the market differently in each region. The major regions covered in the report include North America, Europe, Asia Pacific, the Middle East, and Africa, and others.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=OMR&utm_medium=001

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market, By Solution

6.1 Overview

7 Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Stem Cell Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get a Complete Market Report in your Inbox within 24 hours @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=OMR&utm_medium=001

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Stem Cell Therapy Market Size, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Analysis, Stem Cell Therapy Market Trends, Stem Cell Therapy Market

Here is the original post:
Stem Cell Therapy Market 2019 Analysis by Key Players, Share, Trend, Segmentation and Forecast to 2026 - Instant Tech News

Study shows how a tiny and strange marine animal produces unlimited eggs and sperm over its lifetime – National Institutes of Health

News Release

Thursday, February 13, 2020

NIH-supported research of Hydractinia could provide clues to human reproductive conditions.

A little-known ocean-dwelling creature most commonly found growing on dead hermit crab shells may sound like an unlikely study subject for researchers, but this animal has a rare ability it can make eggs and sperm for the duration of its lifetime. This animal, called Hydractinia, does so because it produces germ cells, which are precursors to eggs and sperm, nonstop throughout its life. Studying this unique ability could provide insight into the development of human reproductive system and the formation of reproductive-based conditions and diseases in humans.

By sequencing and studying the genomes of simpler organisms that are easier to manipulate in the lab, we have been able to tease out important insights regarding the biology underlying germ cell fate determination knowledge that may ultimately help us better understand the processes underlying reproductive disorders in humans, Dr. Andy Baxevanis, director of the National Human Genome Research Institutes (NHGRI) Computational Genomics Unit and co-author of the paper. NHGRI is part of the National Institutes of Health.

In a study published in the journal Science, collaborators at NHGRI, the National University of Ireland, Galway, and the Whitney Laboratory for Marine Bioscience at the University of Florida, Augustine, reported that activation of the gene Tfap2 in adult stem cells in Hydractinia can turn those cells into germ cells in a cycle that can repeat endlessly.

In comparison, humans and most other mammals generate a specific number of germ cells only once in their lifetime. Therefore, for such species, eggs and sperm from the predetermined number of germ cells may be formed over a long period of time, but their amount is restricted. An international team of researchers have been studying Hydractinias genome to understand how it comes by this special reproductive ability.

Hydractinia lives in colonies and is closely related to jellyfish and corals. Although Hydractinia is dissimilar to humans physiologically, its genome contains a surprisingly large number of genes that are like human disease genes, making it a useful animal model for studying questions related to human biology and health.

Hydractinia colonies possess feeding polyps and sexual polyps as a part of their anatomy. The specialized sexual polyps produce eggs and sperm, making them functionally similar to gonads in species like humans.

During human embryonic development, a small pool of germ cells that will eventually become gametes is set aside, and all sperm or eggs that humans produce during their lives are the descendants of those original few germ cells. Loss of these germ cells for any reason results in sterility, as humans do not have the ability to replenish their original pool of germ cells.

In a separate study, Dr. Baxevanis at NHGRI and Dr. Christine Schnitzler at the Whitney Lab have completed the first-ever sequencing of the Hydractinia genome. In this study, researchers used this information to scrutinize the organisms genome for clues as to why there are such marked differences in reproductive capacity between one of our most distant animal relatives and ourselves.

Having this kind of high-quality, whole-genome sequence data in hand allowed us to quickly narrow down the search for the specific gene or genes that tell Hydractinias stem cells to become germ cells, said Dr. Baxevanis.

The researchers compared the behavior of genes in the feeding and sexual structures of Hydractinia. They found that the Tfap2 gene was much more active in the sexual polyps than in the feeding polyps in both males and females. This was a clue that the gene might be important in generating germ cells.

The scientists next confirmed that Tfap2 was indeed the switch that controls the process of perpetual germ cell production. The researchers used the CRISPR-Cas9 gene-editing technique to remove Tfap2 from Hydractinia and measured the resulting effects on germ cell production. They found that removing Tfap2 from Hydractinia stops germ cells from forming, bolstering the theory that Tfap2 controls the process.

The researchers also wanted to know if Tfap2 was influencing specific cells to turn into germ cells. Their analysis revealed that Tfap2 only causes adult stem cells in Hydractinia to turn into germ cells.

Interestingly, the Tfap2 gene also regulates germ cell production in humans, in addition to its involvement in myriad other processes. However, in humans, the germ cells are separated from non-germ cells early in development. Still, despite the vast evolutionary distance between Hydractinia and humans, both share a key gene that changes stem cells into germ cells.

This press release describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose and treat disease. Science is an unpredictable and incremental process each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge of fundamental basic research.

The National Human Genome Research Institute (NHGRI) is one of the 27 institutes and centers at the NIH, an agency of the Department of Health and Human Services. The NHGRI Division of Intramural Research develops and implements technology to understand, diagnose and treat genomic and genetic diseases. Additional information about NHGRI can be found at: https://www.genome.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Read this article:
Study shows how a tiny and strange marine animal produces unlimited eggs and sperm over its lifetime - National Institutes of Health

Flow Cytometry Market to be Worth Over $6.4 Billion by 2027 With CAGR of 8.2%| Top Key Players Like – PharmiWeb.com

Meticulous Research leading global market research company published a research report titledFlow Cytometry Market by Product & Solution (Consumables, Instrument, Software, Service), Technology (Cell-based, Bead-based), Application (Cancer, Immunology, Hematology), and End-user (Pharmaceutical, Biotech, Academia) Global Forecast to 2027.

According to this latest publication from Meticulous Research, the globalFlow Cytometry Market is expected to grow at a CAGR of 8.2% from 2019 to reach to $6.4 billion by 2027. The growth of the flow cytometry market is mainly attributed to the rising global incidence and prevalence of chronic diseases, increasing adoption of flow cytometry techniques in research and academia, and growing initiatives in the field of immunology and immuno-oncology researches. Moreover, the evolving pipeline for stem cell research and the adoption of recombinant DNA technology for antibody production offer significant growth opportunities for the players operating in this market. However, complexities related to reagents development is the key factor expected to hinder the adoption of flow cytometry products to a certain extent.

Access Free Complete Free Sample PDF Copy Here:https://www.meticulousresearch.com/request-sample-report/cp_id=5067

Key questions answered in the report-

Which are the high growth market segments in terms of product & services, technology, application, end-users, and region/countries?What was the historical market for flow cytometry across the globe?What are the market forecasts and estimates for the period 2019-2027?What are the major drivers, restraints, opportunities, and challenges in the overall flow cytometry market?Who are the major players in the flow cytometry market?How is the competitive landscape and who are the market leaders in the overall flow cytometry market?What are the recent developments in the overall flow cytometry market?What are the different strategies adopted by the major players in the overall flow cytometry market?What are the geographical trends and high growth regions/ countries?

Have Any Query? Ask Our Experts Here: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5067

The global flow cytometry market study presents historical market data in terms of values (2017 and 2018), estimated current data (2019), and forecasts for 2027- by product & solution (consumables, instrument, software, service), technology (cell-based, bead-based), application (cancer, immunology, hematology, industrial), end-user (pharmaceutical & biotech companies, research & academia, diagnostic laboratory) forecast to 2027. The study also evaluates industry competitors and analyzes the market at a regional and country level.

Based on technology,the cell-based technology segment held the largest share of the overall flow cytometry market in 2019. The large share of this segment is mainly attributed to the increasing utilization of this technology in research and development activities of novel therapeutic drugs and the advantage of analyzing characteristics and properties of targeted cells with ease. On the other hand, bead-based technology is expected to grow at a higher CAGR during the forecast period owing to the several procedural advantages offered by this technology.

Based on product and solution,the consumables and reagents segment accounted for the largest share of the overall flow cytometry market in 2019 and is expected to grow at the highest CAGR during the forecast period. The commercialization of high-quality application-specific reagents and assays by end-users is supporting the growth of this segment. Also, the continuous requirement of flow cytometry reagents by end-users further supports the growth of this segment.

Based on the end-user,the flow cytometry market is broadly segmented into pharmaceutical & biotechnology companies, diagnostic laboratories, and research & academic institutes. During the forecast period, the diagnostic laboratory segment is expected to register the fastest growth in the flow cytometry market. Some of the major factors contributing to the fastest growth of this segment are rising prevalence of chronic and infectious diseases, growing awareness regarding various chronic diseases, rising willingness to get an accurate diagnosis, and a growing number of laboratories adopting flow cytometers as the advanced diagnostic technology.

Check complete table of contents with a list of table and figures:https://www.meticulousresearch.com/product/flow-cytometry-market-5067/

Geographically, North America commanded the largest share of the global flow cytometry market in 2019, followed by Europe and Asia Pacific. The factors such as the availability of skilled professionals, higher awareness level, and the presence of supportive government reforms for the development of advanced technologies are accelerating the flow cytometry market in the North American region.

Key players:

The key players operating in the global flow cytometry market are Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Apogee Flow Systems Ltd. (U.K.), Sysmex Partec GmbH (Germany), Luminex Corporation (U.S.), Miltenyi Biotec GmbH (Germany), Bio-Rad Laboratories, Inc. (U.S.), bioMrieux S.A. (France), Cytonome/ST LLC (U.S.), Beckman Coulter, Inc. (U.S.), and Becton, Dickinson and Company (U.S.) among others.

Download Sample Report Now !! https://www.meticulousresearch.com/download-sample-report/cp_id=5067

Related Reports:

Infectious Disease Diagnostics Market by Product (Assays and Kits, Instruments, and Software and Services), Technology (Immunodiagnostics, NGS, PCR), Disease Type (Hepatitis, HIV, HPV, Tuberculosis), End User, and Geography Global Forecast to 2025

In Vitro Diagnostics Market | IVD Market By Product (Reagent, Instruments, Software, Service), Technique [Immunoassay, Clinical Chemistry (Lipids, Renal, Thyroid), PCR], Application (Hematology, Diabetes, Nephrology, Oncology), End User (Hospital, POC) Global Forecast to 2024

Contact Us:

Meticulous Research

Email-sales@meticulousresearch.com

Contact Sales- +1-646-781-8004

Connect with us on LinkedIn-https://www.linkedin.com/company/meticulous-research

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at contact@wiredrelease.com.

See original here:
Flow Cytometry Market to be Worth Over $6.4 Billion by 2027 With CAGR of 8.2%| Top Key Players Like - PharmiWeb.com

Global Cord Blood Stem Cell Market Newest Research Report In PDF With Forecast [2020-2029] : Cord Blood Registry Systems Inc, Viacord Inc., China Cord…

The new research report providing thorough analysis on GlobalCord Blood Stem Cell Marketwhich peaks the market size, inclusive market dynamics and high technology updates of Cord Blood Stem Cell market with respect to industry opportunities, threats, challenges, constraints, cost structure and current trend in the market. The Cord Blood Stem Cell industry report is a thorough study of the market where the customer can gain key intuition into the market such as the performance of the market in terms of its market (size and value) for its various segmentations such as storage service, application, and region. This research assists to understand the competitive outlook of Cord Blood Stem Cell market by key players Cord Blood Registry Systems Inc, Viacord Inc., China Cord Blood Corporation., Cord Blood America Inc, Cryo-Cell International Inc, Cryo-Save AG., Cordlife Group Ltd., Vita 34 AG., Lifecell International Pvt. Ltd., Stemcyte Inc..

The research report consists of primary and secondary data which has been further epitomized through various charts, bar graphs, pie charts, tables and market figures. Additionally, detailed landscaping, Cord Blood Stem Cell economic strategy, marketing scheme, as well as SWOT analysis & Porte Five Forces Analysis of the market players have been provided in the Cord Blood Stem Cell report. It also includes the inventive trends, executing a rational pricing stats in the competitive Cord Blood Stem Cell market. The report also categorizes the market in terms of volume and revenue [Million USD].

To Obtain All-Inclusive Information On Forecast Analysis Of GlobalCord Blood Stem CellMarket, Download FREE SamplePDF Report Herehttps://marketresearch.biz/report/cord-blood-stem-cells-market/request-sample

The Cord Blood Stem Cell market report covers revenue number, product details, and sales of the leading Cord Blood Stem Cell corporations. The international market for Cord Blood Stem Cell has been researched with every detail in the publication with increased prominence on various important factors such as opportunities, and self-controlled, growth drivers. Each of the factors that concern to creation of the Cord Blood Stem Cell market dynamics has been studied and analyzed in detail by the Cord Blood Stem Cell analysts, so as to offer the best and most assessing and comprehensive study to the buyers of Cord Blood Stem Cell report.

The snapshot or the directional summary that has been provided in the Cord Blood Stem Cell market intelligence study has been designed in such a way that it will give a quick overview of the market for receiving information on the go. This could assist Cord Blood Stem Cell readers with hands-on data required for decision making during their progress journey in the Cord Blood Stem Cell market.

Global Cord Blood Stem Cell Market Research Report 2020-2029 Includes

Download Free Sample PDF Copy of This Research Report Now!

Geographically, this Cord Blood Stem Cell report is divided into different key regions, with production, Cord Blood Stem Cell utilization, income (million USD), and market share and the rate of growth in these regions, from 2020 to 2029 (forecast), covering Cord Blood Stem Cell market in North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain, etc), South America (Brazil, Argentina, etc), Middle East & Africa Cord Blood Stem Cell market (Saudi Arabia, South Africa, etc) and its Share (%) and CAGR for the predicted period 2020 to 2029.

The Key Points of this Cord Blood Stem Cell Market Report are:

1) To survey and forecast the market size share of Cord Blood Stem Cell, in terms of value and volume.

2) Provide detailed information concerning the Cord Blood Stem Cell major factors (opportunities, drivers, restraints, and industry-specific challenges) influencing the growth of Cord Blood Stem Cell market.

3) To study the future outlook and prospects for the Cord Blood Stem Cell market with Marketing Price (Price and Margin, Factors of Price Change, Manufacturers Gross Margin Analysis)

4) To analyze the global key regions Cord Blood Stem Cell market potential and advantage, opportunity and challenge, restraints and risks.

5) Detail Profile of the dominant players and Cord Blood Stem Cell comprehensively analyses their market status in terms of ranking and core capability along with in-depth the Cord Blood Stem Cell competitive landscape for the market leaders.

6) Study competitive developments like partnerships and joint ventures, Cord Blood Stem Cell new product developments, expansions and research and development of Cord Blood Stem Cell market.

Inquire/Speak To Expert for Further Detailed Information About Cord Blood Stem Cell Report:https://marketresearch.biz/report/cord-blood-stem-cells-market/#inquiry

Note: The historical years of the report and the forecast period can be personalized upon request. [Post Your Research Requirements] In addition, the scope of the published report can be changed as needed, detailed geography or country-based information can be given as part of the customization process.

About Us:

MarketResearch.Biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. The company offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Contact Us:

Mr. Benni Johnson (inquiry@marketresearch.biz)

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Website:https://marketresearch.biz

See the rest here:
Global Cord Blood Stem Cell Market Newest Research Report In PDF With Forecast [2020-2029] : Cord Blood Registry Systems Inc, Viacord Inc., China Cord...

State of the Science for Multiple Myeloma: Change in the Right Direction – Cancer Network

In a workshop held by the FDA in partnership with the American Association for Cancer Research (AACR) on February 13, 2019 in Wardman Park, Washington D.C., researchers from various institutions discussed the current state of African American outcomes and treatment in multiple myeloma trials and the clinical implications.

Although theres still this disparity, the rate of change in the right direction seems to be similar [for Caucasian and African American populations], Kenneth C. Anderson, MD, FAACR, program director for the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at the Dana-Farber Cancer Institute, said of the findings.

In an analysis based on preliminary FDA findings that suggested there was limited enrollment of African Americans in multiple myeloma clinical trials, researchers looked to see if there were differences in outcomes due to race and if there are differences in screen failure rates that contribute to differences in enrollment. Additionally, they looked to address if eligibility criteria are restrictive for certain demographic subgroups.

The presenters, Laura Fernandes, PhD, and Bindu Kanapuru, MD, of the FDA, summarized that enrollment of black patients was significantly less in their pooled dataset compared to white patients. Additionally, there were no conclusive differences in the different racial categories in regard to overall response rate, progression-free survival, and overall survival.

Moreover, more black patients failed to meet the screening criteria than their white and Asian study counterparts. In regard to the screen failure analysis, Kanapuru said, In general, fewer black patients were screened compared to whites and Asians. Second, among those who were screened for enrollment onto the multiple myeloma clinical trials, there is a trend towards higher screen failure rates for blacks compared to white.

Notably, Kanapuru indicated that the FDA has several ongoing initiatives and also published several guidances in an effort to expand eligibility criteria.

Moreover, in an evaluation of characteristics and outcomes of patients with multiple myeloma from an EHR-derived database, Kathleen Maignan, MSN, NP, from Flatiron Health, suggested that researchers were able to assess outcomes in patient subgroups that are likely to have lower representation or even be excluded from trials. Unadjusted results from the database indicated that black patients have similar or better outcomes when compared to white patients. However, adjusting for age and sex minimized this difference, especially for overall survival.

While real world data does have more African American patients, the representation still is not the same, Maignan said.

The research also suggested that black patients have a higher comorbidity burden, which could minimize their consideration for future trials. So, when we look at future directions, given the higher comorbidity burden amongst black patients, we see a potential to conduct future work in this subgroup which may have an unmet need, Maignan said. We also look forward to opportunities to further investigate genomic differences by race as we expand our clinical genomics database and availability there.

Furthermore, covering the scope of the issues, Nikhil C. Munshi, MD, of the Dana-Farber Cancer Institute, indicated that race has significant influence on outcomes and overall survival, as well as age within the different racial groups. Physiological and microenvironment parameters may also play a role with racial differences on outcomes in myeloma according to the researcher. Additionally, traditional prognostic factors may still have variability across racial differences.

So, the critical question now is to study the biological basis for these differences using genomics and all of the different technologies that are directly available to us, Munshi said. Moreover, he recommended that researchers studying patients with multiple myeloma evaluate the impact of race on therapeutic intervention and their PK/PD, as well as disease sensitivity compared to disease resistance.

Looking at biological and genomic differences of multiple myeloma, Shaji K. Kumar, MD, from the Mayo Clinic Cancer Center, Kumar indicated that MGUS is 2-3 times more common in African Americans, which correlates with the fact that myeloma is 2-3 times more common as well. Additionally, he found that there was a trend to earlier age of onset MGUS in blacks compare to whites, with the disparity in prevalence between blacks and whites being most striking within the 40-49 age group (3.26% [95% CI, 2.04-5.18] vs 0.53% [95% CI, 0.20-1.37];P= 0.0013).

I think we want to think about this differently, said Kumar. We are talking about a group of patients who get diagnosed about 10 years younger, who have better biology because of the fundamental underlying genetic differences, despite having advancements at diagnosis they tend to do better, so really the actual setting should be the African Americans should be doing a lot better than what theyre doing now.

The researcher then indicated that important role for screening in the African American patient population, especially with research showing that earlier screening would be beneficial in multiple myeloma. By treating them earlier, he presents the idea that their outcomes could actually be even better than the Caucasian patients. Additionally, Kumar indicated that the access to therapy, specifically stem cell therapy, needs to be addressed.

In the final presentation, Ajay K. Nooka, MD, from the Winship Cancer Institute of Emory University, discussed how to increase minority accrual in myeloma clinical trials through experiences and lessons learned within his own institution. At the system level, a lack of clinical trial infrastructure and insurance were the most prevalent barriers. At the individual level, a lack of trust, fear related to research participation, inadequate information about research, and access/convenience of participation all presented as barriers for clinical trial enrollment.

He listed some solutions that physicians within his institution brought attention to, including:

Following the presentation of the state of the science at the workshop, working groups presented recommendations for how to combat the addressed disparities in African American representation within multiple myeloma clinical trials.

Reference:

FDA-AACR Workshop to Examine Under-representation of African Americans in Multiple Myeloma Clinical Trials. Held Feb. 13, 2020. Wardman Park, Washington D.C.

View original post here:
State of the Science for Multiple Myeloma: Change in the Right Direction - Cancer Network

San Diego News Icon Don Bauder Gives His Heart to Ideal Candidate Bloomberg – Times of San Diego

Share This Article:Mike Bloomberg has a new fan in retired San Diego business journalist and columnist Don Bauder (inset). Photos by Chris Stone, Ellen BauderAt 83, San Diego journalism legend Don Bauder is guarding his health playing hermit at home (to avoid the flu) and venturing out only for doctor visits.

Support Times of San Diego's growthwith a small monthly contribution

Bauder, a Colorado resident since 2003, was forced by heart issues to retire in 2018 as a San Diego Reader columnist. But now he admits hell be questioned about his mental health.

Hes backing Mike Bloomberg for president.

Here I am finally making headway against the heart problems and now I am considered a candidate for the loony bin, Bauder said by email Wednesday.

If exercise and multiple trips to doctors and hospitals will repair my brain as they seem to have helped my heart, I feel I can thwart oncoming dementia, although I have never claimed that I am either stable or a genius as President Donald Trump has. I am at least stable enough to hope that my candidate will not choke on verbal borscht, as Trump does almost every day.

Bauder isnt wearing rose-colored glasses, though.

He concedes that the former New York City mayor once stated that if women wanted to be known for their intelligence, they would spend less time at Bloomingdales and more time at the library.

Bloomberg called the remark a Borscht Belt joke, Bauder said.

The former San Diego Union-Tribune financial editor also noted that Bloomberg once stated that 95% of murderers are male minorities, 15 to 25 who deserve to be pushed up against the wall.

Bauder adds: Democrats desperately need the votes of women, African-Americans and Latinos. New Yorkers have told me that those minorities will never forget, although Bloomberg has renounced his widely criticized stop-and-frisk policy that clearly discriminated against minorities while he was mayor of New York.

But it wasnt until former U-T colleague Logan Jenkins outed himself as a Bloomberg fan that Bauder also emerged from the closet at least locally.

Bauder wrote Times of San Diego:

As a former newspaper columnist and magazine writer, I agree wholeheartedly with Logan Jenkins. After a lot of pondering, I have concluded that Bloomberg is the ideal Democratic candidate. I started out backing Biden, but have become quite disenchanted. Unlike Trump, Bloomberg is a self-made billionaire.

Unlike Trump, who is clearly a sociopath on steroids, as well as a pathological liar and malignant psychotic narcissist, Bloomberg is eminently stable and also brilliant, as he proved in his business career and as mayor of New York City. I would add one thing to what Logan says: we desperately need a female on the ticket. As shown in 2018, females can see through Trump.

I would suggest Kamala Harris; her minority status would help balance the ticket. I worry that Bloombergs stop and frisk mistake will continue to turn off minorities.

Like Bloomberg, Bauder is a former Republican. (From 1960 to 1964, when he was in advertising and PR, Bauder voted for Richard Nixon.)

Since 2004, he says, hes voted for Democratic presidential candidates.

This year, however, I had problems, he wrote Wednesday. I feared that both Bernie Sanders and Elizabeth Warren had gone too far. I dont like Medicare for All. Those who want to keep their private plans should be able to do so. I cant see free higher education for all. Frankly, I think too many students are in college now.

Bauder calls student debt a cancerous problem, but cant see canceling it out.

Should we reimburse those who have already paid off their debt? I cant see giving stipends to families descended from slaves, he said. If anybody deserves to be paid off, its Native Americans, from whom we stole our country.

He said his cautious views left him with moderate choices.

I originally favored Joe Biden, but became disenchanted quickly. I liked Amy Klobuchar from the beginning, and I am happy to see her rising fast, he said. Pete Buttigieg is quite intelligent but needs seasoning. Ditto Tom Steyer.

Bauder considers the 2020 election critical.

Four more years of Trump would be disastrous, he said. Yes, I am concerned about more Russian hacking. Given the close 2016 races in Wisconsin, Michigan and Pennsylvania, we should all worry about Russian hacking this year.

Climate change is the most critical issue for Bauder because if the world doesnt do more to curb greenhouse gases, the world as we know it may suffocate by the end of the century.

This interview was conducted via email.

Times of San Diego: What does Mike Bloomberg offer?

Don Bauder: First: money. Lots of it. Hes worth close to $60 billion, making him 14th-richest in the world, according to Forbes. Unlike Trump, Bloomberg made the money himself. And he is ACTUALLY worth that.

Trump may not even be a billionaire, despite his claims to be worth $10 billion. The biggest advantage of Bloombergs wealth is that he can flood the nation with ads showing that Trump is a phony. Indeed, Bloomberg is already doing that, but you aint seen nuthin yet.

The Democratic Party is hurting for money. Bloomberg is NEEDED. He has not alienated the business community. Right now, money is flowing to Republican coffers because big business particularly pharmaceuticals, insurance, oil and the like is terrified of Sanders and Warren. That river of cash will slow down if the leftists are out of the picture.

As he has proved as New York mayor, Bloomberg is socially liberal and progressive. He supports abortion rights, government-funded stem cell research, same-sex marriage, gun control, environmentalism and routes to citizenship for illegal immigrants.

He is strong on public welfare and is a national leader in the battle against climate change. He wants to enhance the earned income tax credit. But unlike the other candidates, he has support from many in the business community. He is in favor of free trade. He is a fiscal conservative. He balanced New York Citys budget. Facing a crisis, he talked a Republican state Senate into passing a tax increase rather than slashing jobs.

He opposes wealth inequality proposing, for example, that his own taxes should go up. He says generally that taxes for the rich should rise. He would raise corporate taxes from 21% to 28% percent not enough in my judgment, but a good start.

He dislikes the fact that taxes on stock and bond gains are lower than income taxes. He would enhance worker rights and benefits although he has never been considered pro-union. He wants a $15 an hour minimum wage. He favors government-financed welfare projects. He believes rural communities should be more closely connected with urban centers.

During his political career, he has been a Republican, an independent and a Democrat. He knows his way around politics, having been mayor of New York City from 2002 to 2013.

He cracked one time that a short Jew would never be elected president, but I question that. He will absolutely eat up Trump in a debate. It will be obvious that he is 10 times smarter than Trump.

(Bauder cites the same metric in the San Diego mayors race, saying he favors Barbara Bry because of her intelligence.)

Your journalism career is marked by major investigations into scam artists and political boondoggles. What gives you confidence that Bloomberg has genuine concern for the common good and not himself and his affluent cohort?

He favors corporate welfare corporate projects partly funded by government. I consider most such projects to be scams, although few others do. As mayor of New York, he has warned the citizenry of scam artists on the loose. But early in his mayoral term he vetoed a bill against predatory lending.

Why should Sen. Kamala Harris be Bloombergs running mate?

First, the Democrats must have a female on the ticket on the top of the ticket or the vice president. If Bloomberg is at the top, a female must run for the second slot. A minority female would be greatly preferred. Kamala Harris fills that bill. Stacey Abrams or Oprah Winfrey (who says she doesnt want it) would also be excellent.

If Bloomberg doesnt break out in Super Tuesday voting, will he have a shot at winning enough delegates to prevail at Milwaukee Democratic National Convention?

If Bloomberg does poorly, he will have to consider dropping out. If he does drop out, he should continue giving his planned donations to the Democratic Party. Ditto Tom Steyer. Both must continue to give if they are no longer candidates. The Democratic Party is not in good financial shape. If Bloomberg loses, I would hope Sherrod Brown, senator of Ohio, would get in the race.

Bloomberg has credibility from his mayor terms and gun-control and climate-change work. But he was elected in a very liberal environment. Could he challenge Trump in red states?

You make a good point that Bloomberg might not go over well in red states where uneducated voters are abundant. Many Americans hate New Yorkers unfortunately, often for good reasons. But although Bloomberg is short in stature, many voters will realize that he would be the real alpha male in the race. He is tough and knowledgeable. He would take hard stands on many issues.

Handicap a Trump vs. Sanders contest.

Trump has already called Sanders a communist not a socialist, which he is. So we would have a rerun of Joe McCarthy. If Trump continues to call Sanders a communist, Democrats should call Trump and his ilk fascists. Down and dirty. I think Sanders would take the West Coast and most of the East Coast, including Florida.

But Trump would take states where education levels are low the South, and Northern states such as Montana, Wyoming, Idaho, North and South Dakota, Kansas, Nebraska and other traditionally red (redneck?) states. Colorado, New Mexico and even possibly Arizona could go for Sanders.

Ohio, Indiana and Iowa could go red and Wisconsin and Minnesota might go blue. Illinois could stay blue. Much depends on whether Americans realize that Trump is a pathological liar, sociopath, malignant psychotic narcissist. He seems totally out of control now.

Critics like Paul Heideman call Bloomberg a classic oligarch using his wealth to tilt the economic and political playing field in his favor. Can voters trust someone who uses vast wealth to gain support? How is billionaire Bloomberg better suited to the Oval Office than billionaire Steyer (or anyone else)?

Paul Heideman has a point. You are correct that some voters will see how many ads he spreads around and hold his wealth against him. But these people could be swayed by the wave of advertising.

What Bloomberg can do is massively sponsor ads that emphasize that Trump is a liar showing him saying one thing one day and the opposite the next day. Also, such ads could show that Trumps claims about the economy on his watch are false.

For example, Trump keeps repeating that the economy has done better under him than at other times. This is laughably false. GDP is growing a little over 2% now and there have been many times when it grew 3% and even 4%. Trump says unemployment is the lowest ever, and that is also false. These ads can also show Trump at his most vulgar. That might even go over well in redneck territory, however. Trumps racism through his dog whistles could be emphasized in certain markets but not in redneck areas.

Would Bloomberg address wealth inequality?

Bloomberg is strongly opposed to wealth inequality and says his own taxes should go up. However, he would only raise the corporate tax rate to 28% from 21%. Thats not enough, in my judgment. He believes income taxes for the rich should be boosted. He is also disgusted that taxes on stock and bond profits are lower than taxes on incomes.

He complains that economic growth is concentrated in a small number of regions. He would enhance worker rights and benefits although he has never been known as pro-union a possible negative. He wants a $15 minimum wage. He favors government-financed welfare projects. He would like to see rural communities better connected to urban growth centers. He wants to see research and development in regions needing development.

How is your health?

I saw my cardiologist just two weeks ago. I asked him if I was a candidate for a stent in my two arteries that are only moderately good. He said no. (Background: I have had two quadruple-bypass surgeries. The last one was in 1990. On average, the grafts last 30 years.) But cardiologists (I have had several) say this does not mean I have only two years to go.

The heart itself seems to be OK, but the concern is arteries or grafts from previous surgeries filling up. I will be 84 in May. I dont expect to make it to 90, but with lots of luck I may get half or a third of the way there.

San Diego News Icon Don Bauder Gives His Heart to Ideal Candidate Bloomberg was last modified: February 14th, 2020 by Ken Stone

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Read this article:
San Diego News Icon Don Bauder Gives His Heart to Ideal Candidate Bloomberg - Times of San Diego

5 Aesthetic Clinics To Know In The Klang Valley & Their Signature Treatments – Malaysia Tatler

Flawless skin and more beauty fixes at these top aesthetic clinics around town

Sign up for our weekly newsletter to get all our top stories delivered

Were on Facebook and Instagram. Follow us for the latest news, events and happenings

Located at The Shoppes at Four Seasons Place, La Jung is Kuala Lumpurs newest anti-aging and aesthetic clinic, offering anti-aging solutions from Switzerland in partnership with leading Swiss medical clinics.

Helmed by Cardiff-trained aesthetic medical practitioner Dr Nicholas Lim, La Jung spans 5,275sf and comprises five plush treatment rooms, two VIP waiting rooms, a VIP lounge, a VVIP waiting and treatment room, and even a discrete alternative entrance leading directly to the carpark.

Signature treatments: The Sylfirm treatment helps to suppress a common type of skin pigmentation among Asians known as melasma, according Dr. Nicholas. This sophisticated procedure uses technology developed in Silicon Valley, and is typically used to treat melasma in addition to laser treatment in more stubborn cases.

PicoPlus is another specialty of La Jung. It refers to the use of a second-generation pico and nano-second laser to tackle blotchy pigmentation with minimal damage to the surrounding tissue.

Call 03-2856 7616 for more information.

Photos: The Glitz Of La Jung Malaysia's Grand Opening

Beverley Wilshire Medical Centre offers medical aesthetic treatments, anti-ageing medicine, cosmetic surgery, dental aesthetics and hair restoration at its main branch in Jalan Tun Razak. The clinic is known for its non-surgical treatments including V-shape face and nose reshaping.

Signature treatments: A trusted name in cosmetic tourism packages, Beverley Wilshire Medical Centres cosmetic vacation is an all-in-one deal, pairing treatments with an overnight stay at one of its luxury suites or a partner hotel nearby, plus meals, post-op follow-ups and even airport transfers.

Call 03-2118 2888 for more information.

The art of aging gracefully is yours to explore at the Bangsar-based M.A.C Clinic, which specialises in non-invasive or minimally invasive treatments that require little to no downtime.

Offering treatments in body slimming, breast enhancements and laser treatments to preventive age management that targets health risk factors in ones lifestyle, M.A.C clinic is helmed by Dr Hew Yin Keat, a founding member of the Malaysian Society of Aesthetic Medicine.

Signature treatments: Dubbed The Liquid Face Lift, this procedure uses injectable fillers to minimise sagging skin and fine lines without the downtime of plastic surgery, according to Dr Hew. The Picosure Laser treatment is another highly sought-after treatment to improve the appearance of acne, scars and other pigmentation. Other signatures include regenerative medicine, stem cell treatments, the Infini Scar Treatment, and CoolSculpting by Zeltiq.

Call 03-2283 1212 for more information.

Related: MAC Clinic Unveils First PicoSure Laser Treatment in Malaysia In An Exclusive Party At Marinis On 57

Helmed by medical director Prof Dr Edmond Ng (also assistant professor and consultant at the Faculty of Medicine & Health Sciences at UCSI University), Xeoul Clinic boasts a team of full-time consultant aesthetic doctors with more than 10 years of experience.

A beauty clinic under the umbrella of the Xeoul Global brand, Xeoul Clinic specialises in face and skin, weight loss and hair treatments.

Signature treatments: Q-switch NdYag Laser treatment, Fractional CO2 Laser treatment, chemical peels and Regenera Activa for hair enhancement. Weight loss treatments include the BTL Vanquish Me and BTL Vanquish Flex procedures.

Call 03-5613 0023 for more information.

Dr Park Wonjin of Wonjin Beauty Medical Group: Achieving A More Beautiful You

Did you know that Da Vinci Clinic is regularly patronised by one of the cast members of the Netflix series Ghost Bride and feature film The Garden of Evening Mists?

This upscale clinic can be found at The Boulevard Office, Mid Valley City as well as in Cheras and Kepong. It offers face, skin, body and hair treatments in addition to holistic wellness programmes. From dimples creation, lip enhancements and breast augmentation to Botulinum Toxin injections to reduce oversized calves, Da Vinci Clinic operates on the philosophy of helping patients improve on the "minute elements" to unleash the true potential of beauty.

Signature treatments: The Da Vinci Double Eyelid Creation Treatment and Thermage, a non-invasive cosmetic procedure that eases the appearance of stretch marks, wrinkles, fine lines and sagging or uneven skin.

Call 03-2283 2888 for more information.

More here:
5 Aesthetic Clinics To Know In The Klang Valley & Their Signature Treatments - Malaysia Tatler

Tech Ventures kicks off series dedicated to supporting female inventors and entrepreneurs at Johns Hopkins – The Hub at Johns Hopkins

BySaralyn Cruickshank

Of all the things that helped Barb Slusher on her path to becoming a leader in the field of drug discovery and an inventor with more than 70 patents to her name, the relationships she built with her peers, and particularly her female peers, were the most influential. By building relationships, she said, she was able to secure funding for her pharmaceutical ventures while still working in the industry, and the bonds she built with other women in pharma help ensure her voice is heard, even in a room full of men.

"If I look at the people who have invested money in the companies we've started, I've usually started a relationship with that person before. I've consulted for them, I've been to conferences with them, I've been on panels or boards with them. They get to know me and trust me, and that ultimately leads to them investing in my companies. It takes time," said Slusher, a Johns Hopkins alum who now directs the Johns Hopkins Drug Discovery Program. "I'm also used to being the only woman in the room, but when I'm with other women, we team up to make sure that each other's opinions are heard."

Slusher was one of three panelists to share insights about being a woman in innovation during an invitational breakfast event held Wednesday at FastForward U near the Johns Hopkins Homewood campus. Alongside stem cell researcher Sharon Gerecht and biomedical engineer Natalia Trayanova, Slusher spoke to 40 of the university's most prominent women in technology and entrepreneurshipfaculty, staff, and studentswho had gathered to network and share their experiences.

Image credit: Will Kirk / Johns Hopkins University

"I hope that 2020 is a year we acknowledge the lengths that female entrepreneurs go," said Christy Wyskiel, senior advisor to the president of Johns Hopkins University for innovation and entrepreneurship and executive director of Johns Hopkins Technology Ventures. "For Johns Hopkins women, in particular, I am committed to helping them find the sponsorship they need in the form of mentors, investors, board members, and believers in a more equal way."

Hosted by Johns Hopkins Technology Ventures, the event kicked off the AccelHERator event series, a collection of workshops and talks focused on supporting female inventors and entrepreneurs at Johns Hopkins. The series, funded by a grant from the Small Business Association, aims to address the barriers to success experienced by women in tech and business, and to support them and their work. Attendees of the launch event were largely those known by or already working with Tech Ventures, but organizers say they hope more members of the Johns Hopkins community will participate in the program by nominating women entrepreneurs and innovators to join the movement through an online form.

Image credit: Will Kirk / Johns Hopkins University

"The work of bringing research to the market is really difficult, in that it requires both cutting-edge science and a keen understanding of customers and how markets function," said Liz Burger, senior director of strategic initiatives at Tech Ventures. "We need all the talent we can get; we cannot afford to have women participate less. So today is a celebration of the vast potential of women at Johns Hopkins, and the rest of the events in the series are about equipping women with the tools to take action and move ideas forward."

Casey Overby Taylor, an assistant professor of medicine and an expert in biomedical informatics, attended the event to learn more about Tech Ventures and to network with other female entrepreneurs.

"I wanted to explore what it would take to build my own private, commercial business, so this is a good way to get exposed to this topic," Overby Taylor said.

Another attendee, Bailey Surtees, graduated from Johns Hopkins in 2017 and now heads a startup that operates out of FastForward U, the student-focused accelerator and makerspace where the breakfast event was held. She said she was interested in the event because she was looking for an opportunity to connect with other entrepreneurial women.

"The female professors that I had as a student at Hopkins made a big impact on my experience," Surtees said. "Seeing how they balanced being a professional woman at the top of their field and other goals I share with them, like being part of a family, was really cool and helped prepare me for what it's like to be a woman in business."

The next AccelHERator event will be a workshop about creating successful value propositions that help capture potential startup customers and clients. It takes place from 11 a.m. to 1 p.m. on Wednesday, April 1, at FastForward 1812 on the East Baltimore campus. Those interested in attending can register online. Additional events will be held in May and June.

See more here:
Tech Ventures kicks off series dedicated to supporting female inventors and entrepreneurs at Johns Hopkins - The Hub at Johns Hopkins

Study shows how a tiny and strange marine animal produces unlimited eggs and sperm over its lifetime – National Human Genome Research Institute

A little-known ocean-dwelling creature most commonly found growing on dead hermit crab shells may sound like an unlikely study subject for researchers, but this animal has a rare ability it can make eggs and sperm for the duration of its lifetime. This animal, called Hydractinia, does so because it produces germ cells, which are precursors to eggs and sperm, nonstop throughout its life. Studying this unique ability could provide insight into the development of human reproductive system and the formation of reproductive-based conditions and diseases in humans.

By sequencing and studying the genomes of simpler organisms that are easier to manipulate in the lab, we have been able to tease out important insights regarding the biology underlying germ cell fate determination knowledge that may ultimately help us better understand the processes underlying reproductive disorders in humans, Dr. Andy Baxevanis, director of the National Human Genome Research Institutes (NHGRI) Computational Genomics Unit and co-author of the paper. NHGRI is part of the National Institutes of Health.

In a study published in the journal Science, collaborators at NHGRI, the National University of Ireland, Galway, and the Whitney Laboratory for Marine Bioscience at the University of Florida, Augustine, reported that activation of the gene Tfap2 in adult stem cells in Hydractinia can turn those cells into germ cells in a cycle that can repeat endlessly.

In comparison, humans and most other mammals generate a specific number of germ cells only once in their lifetime. Therefore, for such species, eggs and sperm from the predetermined number of germ cells may be formed over a long period of time, but their amount is restricted. An international team of researchers have been studying Hydractinias genome to understand how it comes by this special reproductive ability.

Hydractinia lives in colonies and is closely related to jellyfish and corals. Although Hydractinia is dissimilar to humans physiologically, its genome contains a surprisingly large number of genes that are like human disease genes, making it a useful animal model for studying questions related to human biology and health.

Hydractinia colonies possess feeding polyps and sexual polyps as a part of their anatomy. The specialized sexual polyps produce eggs and sperm, making them functionally similar to gonads in species like humans.

During human embryonic development, a small pool of germ cells that will eventually become gametes is set aside, and all sperm or eggs that humans produce during their lives are the descendants of those original few germ cells. Loss of these germ cells for any reason results in sterility, as humans do not have the ability to replenish their original pool of germ cells.

In a separate study, Dr. Baxevanis at NHGRI and Dr. Christine Schnitzler at the Whitney Lab have completed the first-ever sequencing of the Hydractinia genome. In this study, researchers used this information to scrutinize the organisms genome for clues as to why there are such marked differences in reproductive capacity between one of our most distant animal relatives and ourselves.

Having this kind of high-quality, whole-genome sequence data in hand allowed us to quickly narrow down the search for the specific gene or genes that tell Hydractinias stem cells to become germ cells, said Dr. Baxevanis.

The researchers compared the behavior of genes in the feeding and sexual structures of Hydractinia. They found that the Tfap2 gene was much more active in the sexual polyps than in the feeding polyps in both males and females. This was a clue that the gene might be important in generating germ cells.

The scientists next confirmed that Tfap2 was indeed the switch that controls the process of perpetual germ cell production. The researchers used the CRISPR-Cas9 gene-editing technique to remove Tfap2 from Hydractinia and measured the resulting effects on germ cell production. They found that removing Tfap2 from Hydractinia stops germ cells from forming, bolstering the theory that Tfap2 controls the process.

The researchers also wanted to know if Tfap2 was influencing specific cells to turn into germ cells. Their analysis revealed that Tfap2 only causes adult stem cells in Hydractinia to turn into germ cells.

Interestingly, the Tfap2 gene also regulates germ cell production in humans, in addition to its involvement in myriad other processes. However, in humans, the germ cells are separated from non-germ cells early in development. Still, despite the vast evolutionary distance between Hydractinia and humans, both share a key gene that changes stem cells into germ cells.

This press release describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose and treat disease. Science is an unpredictable and incremental process each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge of fundamental basic research.

Visit link:
Study shows how a tiny and strange marine animal produces unlimited eggs and sperm over its lifetime - National Human Genome Research Institute

Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary…

NEW YORK, Feb. 13, 2020 /PRNewswire/ --Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that presentations from its targeted conditioning portfolio have been accepted for presentation at the 2020 Transplantation & Cellular Therapy (TCT) Meetings, which brings together thousands of transplant professionals from over 500 transplant centers worldwide. TCT is being held February 19-23, 2020 at the Marriott World Center in Orlando, Florida. Notably, data from the pivotal Phase 3 SIERRA trial of Iomab-B have been selected for an oral presentation.

"We are excited that Iomab-B and the SIERRA trial have once again been selected as an oral presentation at TCT," said Dr. Mark Berger, Chief Medical Officer of Actinium. "We look forward to highlighting the potential benefit that Iomab-B can provide to a patient population with active disease who are otherwise ineligible for BMT. We are confident these findings will be received with great enthusiasm. TCT, which assembles leading transplant physicians from top centers in the United States and worldwide, is the ideal venue to showcase the extremely encouraging findings from the SIERRA trial thus far. In addition, our other conference activities are expected to provide significant exposure for this important trial and invaluable interactions with BMT thought leaders. Through the SIERRA trial, we aspire to change the treatment paradigm for older patients with relapsed or refractory AML to make potentially curative BMT via Iomab-B the standard of care for this patient population that continues to have poor outcomes."

Actinium's TCT Presentations:

Late Breaking Oral Presentation:

Poster Presentation:

About the SIERRA TrialThe SIERRA trial (Study ofIomab-B inElderlyRelapse/RefractoryAcute Myeloid Leukemia) is the only randomized Phase 3 trial that offers BMT (Bone Marrow Transplant) as an option for older patients with active, relapsed or refractory AML or acute myeloid leukemia. BMT is the only potentially curative treatment option for older patients with active relapsed or refractory AML and there is no standard of care for this indication other than salvage therapies. Iomab-B is an ARC (Antibody Radiation-Conjugate) comprised of the anti-CD45 antibody apamistamab and the radioisotope I-131 (Iodine-131). The 20 active SIERRA trial sites in the U.S. and Canada represent many of the leading bone marrow transplant centers by volume. For more information, visit http://www.sierratrial.com.

About Transplantation & Cellular Therapy Meetings (TCT) TCT, formerly known as the BMT Tandem Meetings, are the combined annual meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR).Each year the conference brings together several thousand investigators, clinicians, researchers, nurses and other allied health professionals from over 500 transplant centers from over 50 countries around a full scientific program focused on bone marrow transplant and cellular therapies.

About Actinium Pharmaceuticals, Inc. (NYSE: ATNM)Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3Study ofIomab-B inElderlyRelapsed orRefractoryAcute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial is over fifty percent enrolled and promising single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. I-131 apamistamab will also be studied as a targeted conditioning agent in a Phase 1/2 anti-HIV stem cell gene therapy with UC Davis and is expected to be studied with a CAR-T therapy in 2020. In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Ongoing combination trials include our CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax. Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform. This is where our intellectual property portfolio of over 100 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes. Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc. Website: https://www.actiniumpharma.com/

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Contacts:

Investors:Hans Vitzthum LifeSci Advisors, LLCHans@LifeSciAdvisors.com(617) 535-7743

Media:Alisa Steinberg, Director, IR & Corp Commsasteinberg@actiniumpharma.com(646) 237-4087

SOURCE Actinium Pharmaceuticals, Inc.

http://www.actiniumpharma.com/

See more here:
Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary...